David Bonita, M.D.

Partner, Orbimed

David is a Partner on the private equity team. Prior to joining OrbiMed, Dr. Bonita worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS.

+ Show More

Jerel Davis, PhD

Managing Director, Versant Ventures

Jerel is a Managing Director based at Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups.

+ Show More

Todd Foley

Managing Director, MPM Capital

Todd is a Managing Director at MPM Capital. He focuses on biotech investments, and in addition to serving on Repare’s board, he serves on a number of MPM portfolio company boards, including Switch Bio, Chiasma (CHMA), ClinicalInk, Iconic, Rhythm, Semma and Tetherex.

+ Show More

Sam Kulkarni

CEO, CRISPR Therapeutics

Sam has served as CEO of CRISPR Therapeutics since 2017. He has significant expertise in strategy and operations in biotechnology and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer.

+ Show More

Briggs W. Morrison, MD

CEO, Syndax Pharmaceuticals

Briggs is the CEO of Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm.

+ Show More

Kevin Raidy

Managing Partner, Cowen Healthcare Investments

Kevin is Managing Partner, Cowen Healthcare Investments. Previously, Mr. Raidy was Cowen’s Head of Investment Banking and prior to that he served as co-head of Cowen’s equity capital markets group, which is responsible for the origination and execution of all equity capital-raising transactions. Before that, he was a managing director at Cowen Investment Management (formerly known as Ramius LLC), where he was portfolio manager for direct investments and convertible bonds. Mr. Raidy also was the founder of H4 Capital Management LLC.

+ Show More

Carol Schafer

Financial Professional

Carol is a seasoned financial professional with more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development. She most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities.

+ Show More

Lloyd M. Segal

President & CEO, Repare Therapeutics

In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.

+ Show More